---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-003673"
form_type: "8-K"
ticker: "AMIX"
cik: "0001617867"
company_name: "Autonomix Medical, Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:19:18.928964+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Autonomix Medical reports Q3 FY2025 net loss of $2.7M, cash $11.8M; PoC trial data on track for 1H2025

## Summary
- Net loss of $2.7M for Q3 ended Dec 31, 2024 vs $3.1M a year ago; nine-month net loss $8.2M vs $10.0M.
- Cash position $11.8M as of Dec 31, 2024; raised $10M in underwritten public offering during the quarter.
- Topline proof-of-concept trial data for pancreatic cancer pain expected in 1H2025; US clinical trials targeted for 2H2025.
- Achieved design lock for RF ablation catheter after successful animal testing; expanded IP with new U.S. patent grant.
- Targeting De Novo submission in 2026 and potential FDA clearance for pancreatic cancer pain in 2027.

## SEC filing metadata
- accession: 0001437749-25-003673
- form_type: 8-K
- ticker: AMIX
- cik: 0001617867
- company_name: Autonomix Medical, Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617867/000143774925003673/0001437749-25-003673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617867/000143774925003673/amix20250210_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-003673
- JSON: https://secwatch.observer/filing/0001437749-25-003673.json
- Plain text: https://secwatch.observer/filing/0001437749-25-003673.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.